Talis Group

Twenty-Four Rising Black Professionals Step Forward: TALI Celebrates Graduates of Its New "Emerging Leaders Program"

Retrieved on: 
Wednesday, April 6, 2022
Giant, UPMC, Emergency Leaders for Climate Action, Carnegie Mellon University, CEO, Program, Tepper School of Business, BNY Mellon, University, Executive, Real estate development, Bank of America, Global Leaders Program, Faculty, Senior, China Executive Leadership Academy in Pudong, Leadership, PNC, Harvard University Advanced Leadership Initiative, Neighbourhood, Carnegie, Heinz Endowments, University of Pittsburgh, Multimedia, PNC Financial Services, Business, Greater Pittsburgh Region, Academy, Carnegie Museum, Buchanan Ingersoll & Rooney, Government, Duquesne University, Bank, Robert Morris University, Talis Group, Partnership, EY, Richard King Mellon, CMU, Duquesne Light Company, Inclusion, Foundation, Giant Eagle, City, Management, Medicine, Covestro, Art, Black, Koppers, Sheetz, Northwestern Mutual

The Emerging Leaders Program provides critical support for high-potential Black leaders of tomorrow and is designed to help prepare them for advancement.

Key Points: 
  • The Emerging Leaders Program provides critical support for high-potential Black leaders of tomorrow and is designed to help prepare them for advancement.
  • Twenty-Four ELP graduates commemorated a transformative step in their professional journey by completing the program.
  • Celebrating alongside the graduates were Pittsburgh Mayor Ed Gainey and Keynote Speaker Marsha Jones (TALI Board Chair and Executive Vice President/Diversity and Inclusion Executive of PNC).
  • "The 2022 Emerging Leaders Program graduates represent TALI's commitment to support and cultivate the next generation of Black leaders," states Evan Frazier (President & CEO, The Advanced Leadership Institute).

Talis Biomedical to Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, July 27, 2021
Prionapterygini, Library automation, Talis Group, Talis, Information science, Molecular diagnostics, Articles, Biology

MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021.

Key Points: 
  • MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021.
  • Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results.
  • A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedicals website at www.talis.bio .
  • The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Talis Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of its Talis One™ COVID-19 Test

Retrieved on: 
Monday, March 8, 2021
Natural sciences, Pharmaceutical industry, Articles, Health sciences, Validity, COVID-19 testing, Clinical Laboratory Improvement Amendments, Assay, Comparator, Validation, Talis Group, Talis

In late February, the FDAinformed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity to support Taliss EUA application.

Key Points: 
  • In late February, the FDAinformed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity to support Taliss EUA application.
  • Talis intends to initiate its previously planned clinical validation study in a point-of-care environment, with plans to submit an EUA application for the Talis One COVID-19 test in CLIA waived settings early in the second quarter of 2021.
  • The planned clinical validation study was designed with a different comparator assay, which Talis believes will address the FDAs concerns.
  • Given the recent correspondence from the Agency and its stated prioritization of point-of-care platforms, we feel this course of action offers a faster path to market.

Talis Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, February 12, 2021
Finance, Financial markets, Money, Initial public offering, Corporate finance, Library automation, Talis Group, Underwriting, Public offering, Talis, NASDAQ

MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of its common stock at a public offering price of $16.00 per share.

Key Points: 
  • MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of its common stock at a public offering price of $16.00 per share.
  • The gross proceeds to Talis from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Talis, are expected to be approximately $220.8 million.
  • In addition, Talis has granted the underwriters a 30-day option to purchase up to 2,070,000 additional shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.
  • The company is developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Talis Appoints Melissa L. Gilliam, M.D., M.P.H., to Board of Directors

Retrieved on: 
Wednesday, January 27, 2021
Library automation, Talis Group, Reproductive health, Talis, Information science, Companies, Academic disciplines

Dr. Gilliam is the Ellen H. Block Professor of Health Justice and Vice Provost of the University of Chicago.

Key Points: 
  • Dr. Gilliam is the Ellen H. Block Professor of Health Justice and Vice Provost of the University of Chicago.
  • "As a practicing physician and academician with deep experience in women's health and reproductive and sexual health, Melissa is a valuable addition to our Board," said Brian Coe, Co-founder and Chief Executive Officer of Talis.
  • Affecting millions of people worldwide, STIs cause serious illness and adversely impact people's quality of life," said Dr. Gilliam.
  • I look forward to sharing my insights and experience in academic medicine with my fellow Board members and the Talis team."

Talis Expands Executive Team and Closes Additional Financing in Preparation for Commercial Launch of Talis One™ System

Retrieved on: 
Thursday, November 12, 2020
Library automation, Talis Group, Talis, Companies

Additionally, it has closed a new $126 million financing to support expansion of its operations and the commercial scale-up of the Talis One System and further expand the test menu.

Key Points: 
  • Additionally, it has closed a new $126 million financing to support expansion of its operations and the commercial scale-up of the Talis One System and further expand the test menu.
  • The Talis One System is a sample-to-answer, cloud-enabled, molecular diagnostic platform designed to provide rapid and highly accurate point-of-care tests for the detection of infectious diseases, including COVID-19.
  • Mr. Kelley brings to Talis more than two decades of sales and commercial leadership experience.
  • In this newly created role, he will be responsible for commercial operations and will oversee the potential commercial launch of the Talis One System, initially for COVID-19 and subsequently for other infectious diseases.

Talis Awarded NIH RADx Contract to Launch Talis One™ System for Point-of-Care COVID-19 Testing and Further Strengthens Financial Position and Leadership Team

Retrieved on: 
Friday, July 31, 2020
Medicine, Medical tests, Medical terminology, Point-of-care testing, Talis Group, Infectious disease, Talis, Infection, Health, Articles

This important funding will accelerate the commercialization of our Talis One System for the detection of COVID-19.

Key Points: 
  • This important funding will accelerate the commercialization of our Talis One System for the detection of COVID-19.
  • Roger Moody, Talis' new Chief Financial Officer, is an accomplished finance executive with a wealth of experience in finance operations.
  • The Talis One System is a compact, easy-to-use, highly accurate molecular diagnostic platform developed to enable rapid, point-of-care testing for infectious diseases.
  • Talis is dedicated to providing broad access to fast, highly accurate, actionable diagnostic testing to ensure better treatment and disease management for patients with infectious diseases.

Talis Awarded NIH RADx Contract to Launch Talis One™ System for Point-of-Care COVID-19 Testing and Further Strengthens Financial Position and Leadership Team

Retrieved on: 
Friday, July 31, 2020
Medicine, Medical tests, Medical terminology, Point-of-care testing, Talis Group, Infectious disease, Talis, Infection, Health, Articles

This important funding will accelerate the commercialization of our Talis One System for the detection of COVID-19.

Key Points: 
  • This important funding will accelerate the commercialization of our Talis One System for the detection of COVID-19.
  • Roger Moody, Talis' new Chief Financial Officer, is an accomplished finance executive with a wealth of experience in finance operations.
  • The Talis One System is a compact, easy-to-use, highly accurate molecular diagnostic platform developed to enable rapid, point-of-care testing for infectious diseases.
  • Talis is dedicated to providing broad access to fast, highly accurate, actionable diagnostic testing to ensure better treatment and disease management for patients with infectious diseases.

Terumo Cardiovascular Group and Talis Clinical Introduce ACG-Perfusion™ and ACG-RemoteView™ Systems, Enhancing Efficiency of Clinical Care Team

Retrieved on: 
Tuesday, May 7, 2019
Intensive care medicine, Health, Terumo, Talis Group, Extracorporeal membrane oxygenation, Intensive care unit, Talis, Perfusion

Terumo and Talis announced a strategic partnership in January 2019 which enables Terumo to distribute Talis Clinical's ACG-Perfusion and ACG-RemoteView Systems in cardiac operating rooms and intensive care units.

Key Points: 
  • Terumo and Talis announced a strategic partnership in January 2019 which enables Terumo to distribute Talis Clinical's ACG-Perfusion and ACG-RemoteView Systems in cardiac operating rooms and intensive care units.
  • Terumo and Talis have future plans to expand distribution of the systems globally, as well as develop a unique application for ECMO management.
  • Deployed in the OR, the Talis ACG-Perfusion System allows for safe and efficient care by automatically collecting all relevant perfusion data at the point of care.
  • Today Talis Clinical software solutions have expanded beyond anesthesia to the CVOR and CVICU supporting hospitals across the country.

Talis Capital Expands and Strengthens the Investment Team

Retrieved on: 
Wednesday, December 19, 2018
Economy, Private equity, Entrepreneurship, Corporate finance, Equity securities, Venture capital, Talis Group

The team has also added two Investment Executives, Scott Fransen and Davide Richardson to support the investment team.

Key Points: 
  • The team has also added two Investment Executives, Scott Fransen and Davide Richardson to support the investment team.
  • "Originally founded in 2009 from a small family office, Talis Capital has evolved significantly over the last 10 years to become one of the leading venture capital investment firms in London today.
  • Talis Capital is a unique Venture Capital investment firm funded by a group of successful and strategic high net worth entrepreneurs.
  • Talis Capital Limited ("Talis") is an appointed representative of Privium Fund Management (UK) Limited ("Privium").